Having demonstrated the presence of PTPRM promoter hypermethylation associated transcription silencing (Fig. 4A and B), we studied if PTPRM epigenetic loss in cancer patients had any impact on the clinical outcome in these patients. The gene discussed is PTPRM; the disease is cancer.